TY - JOUR
T1 - Direct oral anticoagulants in asian patients with atrial fibrillation
T2 - Consensus recommendations by the Asian Pacific Society of Cardiology on strategies for thrombotic and bleeding risk management
AU - Chong, Daniel T.T.
AU - Andreotti, Felicita
AU - Verhamme, Peter
AU - Dalal, Jamshed J.
AU - Uaprasert, Noppacharn
AU - Wang, Chun Chieh
AU - On, Young Keun
AU - Li, Yi Heng
AU - Jiang, Jun
AU - Hasegawa, Koji
AU - Almuti, Khalid
AU - Bai, Rong
AU - Lo, Sidney T.H.
AU - Krittayaphong, Rungroj
AU - Lee, Lai Heng
AU - Quek, David K.L.
AU - Johar, Sofian
AU - Seow, Swee Chong
AU - Hammett, Christopher J.
AU - Tan, Jack W.C.
N1 - Funding Information:
Disclosure: This work was funded through the Asian Pacific Society of Cardiology with unrestricted educational grants from Abbott Vascular, Amgen, AstraZeneca, Bayer and Roche Diagnostics. DC has received honoraria from Abbott, Biotronik, Boston Scientific, Boehringer Ingelheim, Johnson & Johnson, Medtronic and Pfizer. FA has received honoraria outside the present work from Amgen, Bayer, BI, BMS, Daiichi Sankyo and Pfizer. PV has received honoraria from Bayer, BI, BMS, Daiichi Sankyo, Leo Pharma, Pfizer and Portola; and research grants from Bayer, Boehringer Ingelheim and Bristol Meyers Squibb. JJD has received honoraria from Bayer and Pfizer. CCW has received honoraria and research grants from Bayer, BI, Daiichi Sankyo and Pfizer. YHL has received honoraria from Amgen, AstraZeneca, Bayer, BI, Daiichi Sankyo, Roche and Sanofi. JJ has received honoraria from Abbott Vascular, Amgen, AstraZeneca, Bayer, Boston Scientific, Medtronic and Pfizer. STHL has received honoraria and travel support from Abbott, Bayer, Bioexcel, BI, Boston Scientific, Medtronic and Pfizer. LHL has received education and travel grants from Sanofi. DQ has received honoraria from Bayer and Pfizer. SJ has received honoraria from Biosense Webster and Medtronic. SCS has received honoraria from Abbott, Bayer, Biotronik and Medtronic. CJH has received honoraria from Amgen, Bayer, BI and Pfizer-MSD. JWCT has received honoraria from Abbott Vascular, Amgen, AstraZeneca, Bayer, Boston Scientific, BI, Medtronic, Orbus Neich and Biotronik; and research grants from Abbott Diagnostics and Beckmann. All other authors have no conflicts of interest to declare. Acknowledgement: Medical writing support was provided by Tan Ee Min and Ivan Olegario of MIMS Pte Ltd. Received: 23 October 2020 Accepted: 27 December 2020 Citation: European Cardiology Review 2021;16:e23. DOI: https://doi.org/10.15420/ecr.2020.43 Correspondence: Jack Wei Chieh Tan, National Heart Centre, 5 Hospital Dr, Singapore 169609, Singapore. E: [email protected] Open Access: This work is open access under the CC-BY-NC 4.0 License which allows users to copy, redistribute and make derivative works for non-commercial purposes, provided the original work is cited correctly.
Publisher Copyright:
© Radcliffe Cardiology 2021
PY - 2021
Y1 - 2021
N2 - The disease burden of AF is greater in Asia-Pacific than other areas of the world. Direct oral anticoagulants (DOACs) have emerged as effective alternatives to vitamin K antagonists (VKA) for preventing thromboembolic events in patients with AF. The Asian Pacific Society of Cardiology developed this consensus statement to guide physicians in the management of AF in Asian populations. Statements were developed by an expert consensus panel who reviewed the available data from patients in Asia-Pacific. Consensus statements were developed then put to an online vote. The resulting 17 statements provide guidance on the assessment of stroke risk of AF patients in the region, the appropriate use of DOACs in these patients, as well as the concomitant use of DOACs and antiplatelets, and the transition to DOACs from VKAs and vice versa. The periprocedural management of patients on DOAC therapy and the management of patients with bleeding while on DOACs are also discussed.
AB - The disease burden of AF is greater in Asia-Pacific than other areas of the world. Direct oral anticoagulants (DOACs) have emerged as effective alternatives to vitamin K antagonists (VKA) for preventing thromboembolic events in patients with AF. The Asian Pacific Society of Cardiology developed this consensus statement to guide physicians in the management of AF in Asian populations. Statements were developed by an expert consensus panel who reviewed the available data from patients in Asia-Pacific. Consensus statements were developed then put to an online vote. The resulting 17 statements provide guidance on the assessment of stroke risk of AF patients in the region, the appropriate use of DOACs in these patients, as well as the concomitant use of DOACs and antiplatelets, and the transition to DOACs from VKAs and vice versa. The periprocedural management of patients on DOAC therapy and the management of patients with bleeding while on DOACs are also discussed.
UR - http://www.scopus.com/inward/record.url?scp=85108117546&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85108117546&partnerID=8YFLogxK
U2 - 10.15420/ECR.2020.43
DO - 10.15420/ECR.2020.43
M3 - Article
AN - SCOPUS:85108117546
SN - 1758-3756
VL - 16
JO - European Cardiology Review
JF - European Cardiology Review
M1 - e23
ER -